NCT02574286 - Study of the Effect of Velaglucerase Alfa (VPRIV®) on Bone-related Pathology in Treatment-naïve Participants With Type 1 Gaucher Disease | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 29, 2016

Primary Completion Date

November 12, 2020

Study Completion Date

November 30, 2020

Conditions

Gaucher Disease

Interventions

DRUG

Velaglucerase alfa

Participants will receive 60-minute intravenous infusion of 60 U/kg velaglucerase alfa EOW.

DIETARY_SUPPLEMENT

Vitamin D

Participants will receive 800 IU vitamin D orally daily.

Trial Locations (15)

10016

NYU School of Medicine, New York

19104

The Children's Hospital of Philadelphia, Philadelphia

22030

Lysosomal and Rare Disorders Research and Treatment Center, Fairfax

27710

Duke University Medical Center, Durham

28034

Hospital Universitario Ramon y Cajal, Madrid

30322

Emory Genetics, Atlanta

49100

Rabin Medical Center, Petah Tikva

50006

Hospital Quironsalud Zaragoza, Zaragoza

60611

Ann and Robert H Lurie Childrens Hospital of Chicago, Chicago

90027

Kaiser Permanente, Los Angeles

90211

Cedars Sinai Medical Center, Beverly Hills

91031

Shaare Zedek Medical Center, Jerusalem

3109601

Rambam Health Care Campus, Haifa

CB20QQ

Addenbrooke's Hospital, Cambridge

NW3 2QG

Royal Free Hospital, London